Exenatide alters myocardial glucose transport and uptake depending on insulin resistance and increases myocardial blood flow in patients with type 2 diabetes

Journal of Clinical Endocrinology and Metabolism

Volumn 97, Issue 7, 2012, Pages

  Gejl, M ^a   Sondergaard H M ^b   Stecher, C ^a   Bibby, B M ^a   Moller N ^c   Botker H E ^c   Hansen, S B ^c   Gjedde, A ^c,d   Rungby, Jørgen ^a   Brock, B ^a  

^a AARHUS UNIVERSITY   (Denmark)

^b VIBORG HOSPITAL   (Denmark)

^c AARHUS UNIVERSITY HOSPITAL   (Denmark)

^d UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

AMMONIA N 13; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; C PEPTIDE; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; EXENDIN 4; FLUORODEOXYGLUCOSE F 18; GLUCAGON LIKE PEPTIDE 1; GLUCOSE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; METFORMIN; PLACEBO; SULFONYLUREA DERIVATIVE;

ADULT; ARTICLE; CELL MEMBRANE; CLINICAL ARTICLE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CROSSOVER PROCEDURE; DIABETIC PATIENT; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG EFFECT; GLUCOSE CLAMP TECHNIQUE; GLUCOSE TRANSPORT; GLUCOSE UTILIZATION; HEART MUSCLE BLOOD FLOW; HEART MUSCLE CELL; HEART PROTECTION; HUMAN; INSULIN RESISTANCE; MALE; METABOLITE; MYOCARDIAL GLUCOSE TRANSPORT; NON INSULIN DEPENDENT DIABETES MELLITUS; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

BIOLOGICAL TRANSPORT; CORONARY CIRCULATION; CROSS-OVER STUDIES; DIABETES MELLITUS, TYPE 2; DOUBLE-BLIND METHOD; GLUCOSE; HEART; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN RESISTANCE; MALE; MIDDLE AGED; MYOCARDIUM; PEPTIDES; PLACEBOS; POSITRON-EMISSION TOMOGRAPHY; REGIONAL BLOOD FLOW; UP-REGULATION; VENOMS;

EID: 84863580185     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2011-3456     Document Type: Article

References (18)

1. Morrish NJ, Wang SL, Stevens LK, Fuller JH, Keen H 2001 Mortality and causes of death in the WHO Multinational Study of Vascular Disease in Diabetes. Diabetologia 44(Suppl 2):S14-S21 (Pubitemid 32844108)
2. Holst JJ 2004 On the physiology of GIP and GLP-1. Horm Metab Res 36:747-754 (Pubitemid 40115894)
3. Ban K, Noyan-Ashraf MH, Hoefer J, Bolz SS, Drucker DJ, Husain M 2008 Cardioprotective and vasodilatory actions of glucagon-like peptide 1 receptor are mediated through both glucagon-like peptide 1 receptor-dependent and -independent pathways. Circulation 117:2340-2350 (Pubitemid 351653542)
4. Best JH, Hoogwerf BJ, Herman WH, Pelletier EM, Smith DB, Wenten M, Hussein MA 2011 Risk of cardiovascular disease events in patients with type 2 diabetes prescribed the glucagon-like peptide 1 (GLP-1) receptor agonist exenatide twice daily or other glucose-lowering therapies: a retrospective analysis of the LifeLink database. Diabetes Care 34:90-95
5. Lerche S, Brock B, Rungby J, Bøtker HE, Møller N, Rodell A, Bibby BM, Holst JJ, Schmitz O, Gjedde A 2008 Glucagon-like peptide-1 inhibits blood-brain glucose transfer in humans. Diabetes 57:325-331
6. Degn KB, Brock B, Juhl CB, Djurhuus CB, Grubert J, Kim D, Han J, Taylor K, Fineman M, Schmitz O 2004 Effect of intravenous infusion of exenatide (synthetic exendin-4) on glucose-dependent insulin secretion and counterregulation during hypoglycemia. Diabetes 53:2397-2403 (Pubitemid 39145595)
7. WallaceT M, Levy JC, Matthews DR 2004 Use and abuse of HOMA modeling. Diabetes Care 27:1487-1495 (Pubitemid 38680001)
8. Søndergaard HM, Bøttcher M, Marie Madsen M, Schmitz O, Hansen SB, Nielsen TT, Bøtker HE 2006 Impact of type 2 diabetes on myocardial insulin sensitivity to glucose uptake and perfusion in patients with coronary artery disease. J Clin Endocrinol Metab 91:4854-4861 (Pubitemid 44917318)
9. Bøtker HE, Böttcher M, Schmitz O, Gee A, Hansen SB, Cold GE, Nielsen TT, Gjedde A 1997 Glucose uptake and lumped constant variability in normal human hearts determined with [18F]fluorodeoxyglucose. J Nucl Cardiol 4:125-132
10. Vyas AK, Yang KC, Woo D, Tzekov A, Kovacs A, Jay PY, Hruz PW 2011 Exenatide improves glucose homeostasis and prolongs survival in a murine model of dilated cardiomyopathy. PLoS One 6:e17178
11. Bhashyam S, Fields AV, Patterson B, Testani JM, Chen L, Shen YT, Shannon RP 2010 Glucagon-like peptide-1 increases myocardial glucose uptake via p38α MAP kinase-mediated, nitric oxide-dependent mechanisms in conscious dogs with dilated cardiomyopathy. Circ Heart Fail 3:512-521
12. Ding SY, Nkobena A, Kraft CA, Markwardt ML, Rizzo MA 2011 Glucagon-like peptide 1 stimulates post-translational activation of glucokinase in pancreatic β cells. J Biol Chem 286:16768-16774
13. Morita K, Katoh C, Yoshinaga K, Noriyasu K, Mabuchi M, Tsukamoto T, Kageyama H, Shiga T, Kuge Y, Tamaki N 2005 Quantitative analysis of myocardial glucose utilization in patients with left ventricular dysfunction by means of 18F-FDG dynamic positron tomography and three-compartment analysis. Eur J Nucl Med Mol Imaging 32:806-812 (Pubitemid 41125423)
14. Wasserman DH, Ayala JE 2005 Interaction of physiological mechanisms in control of muscle glucose uptake. Clin Exp Pharmacol Physiol 32:319-323 (Pubitemid 40586069)
15. Davidson MH 2011 Cardiovascular effects of glucagon-like peptide-1 agonists. Am J Cardiol 108:33B-41B
16. Dokken BB, Hilwig WR, Teachey MK, Panchal RA, Hubner K, Allen D, Rogers DC, Kern KB 2010 Glucagon-like peptide-1 (GLP-1) attenuates post-resuscitation myocardial microcirculatory dysfunction. Resuscitation 81:755-760
17. Gill A, Hoogwerf BJ, Burger J, Bruce S, Macconell L, Yan P, Braun D, Giaconia J, Malone J 2010 Effect of exenatide on heart rate and blood pressure in subjects with type 2 diabetes mellitus: a double-blind, placebo-controlled, randomized pilot study. Cardiovasc Diabetol 9:6
18. Edwards CM, Stanley SA, Davis R, Brynes AE, Frost GS, Seal LJ, Ghatei MA, Bloom SR 2001 Exendin-4 reduces fasting and post-prandial glucose and decreases energy intake in healthy volunteers. Am J Physiol Endocrinol Metab 281:E155-E161